Ignite Creation Date:
2024-05-05 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 9:52 AM
Study NCT ID:
NCT00719212
Status:
COMPLETED
Last Update Posted:
2016-01-11
First Post:
2008-07-18
Brief Title:
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Sponsor:
Translational Research in Oncology
Organization:
Translational Research in Oncology
Study Overview
Official Title:
A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479 a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor IGF-1R as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to obtain an estimate of the objective response rate ORR of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial including fallopian tube and primary peritoneal carcinoma failing frontline chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None